Thank you Carl. Slide Number 7 outlines selective profit and loss statement information for the company for the three and 12 months ended December 31, 2016, compared to the same information for the period ended December 31, 2015. The gross margin improvements were primarily the result of a higher production yield from donors in our biologics division, as well as the higher average sales price for the Company’s fiber and OsteoSelect products. Consolidate total revenue for the three months ended December 31, 2016 was approximately $24.5, an increase of 10%, compared to $22.3 million of revenue for the same period of 2015. Consolidated total revenue for the 12 months ended December 31, 2016 was approximately $90 million, an increase of 4% from pro forma revenue of approximately $86.5 million for the same period of 2015. Excluding OEM revenue from Zimmer consolidated total core revenue growth were 5.9% for the 12 months ended December 31, 2016 compared to 2015. Consolidated gross profit for the fourth quarter of 2016 was $17.5 million or 71.6% of revenue, compared to gross profit of $14.9 million or 67% of revenues for the fourth quarter of 2015. As I mentioned, the gross margin improvements were primarily the result of a higher production yield from donors as well as a higher average selling price for the company’s fiber and OsteoSelect products. For the year, consolidated gross profit was approximately $62.3 million compared with pro forma 2015 gross profit of $56.6 million. Gross margin for the year was 69.2% compared to 2015 pro forma gross margin of 65.4%, a growth of 3.8%. The company defines earnings before interest, taxes, depreciation and amortization or EBITDA as net income loss from operations before depreciation, amortization, impairment charges, non-recurring expenses and non-cash stock-based compensation. Consolidated EBITDA for the fourth quarter of 2016 was a gain of $1.2 million compared to a pro forma loss of $350,000 for the same period during 2015. Full year 2016 EBITDA was a gain of $2 million compared to a pro forma loss of $33,000 in the prior year as shown in Slide Number 8. With respect to our balance sheet which is shown on Slide Number 9, you could see total assets of $144 million were reported at December 31, 2016 and this includes approximately $19 million of net accounts receivable and $27.2 million of inventory. Total liabilities include approximately $70.2 million of convertible debt and $50.6 million of senior secured debt. OrbiMed Advisors, our largest stakeholder holds approximately $54 million of the convertible debt balance and the entire amount of the senior secured debt in addition to owning between 3% and 4% of our outstanding common shares as of December 31, 2016. Slide Number 10 outlines the leverage of incremental revenues once breakeven has achieved. We define breakeven as EBITDA less total cash based interest expense. Essentially, the revenues were acquired to cover our cash based operating expenses and interest expense. Quarterly breakeven occurs at approximately $25 million of revenue. On an incremental basis, after breakeven is achieved, Xtant expects incremental profit margin of approximately 42% as shown on the Slide Number 10. Essentially, for each $1 million of additional revenue after breakeven is achieved, approximately $420,000 or 42% of operating profit would drop to the bottom line. Slide Number 11, outlines our short-term objectives to achieve breakeven, allowing us to generate free cash flow after interest expense on incremental revenues above that breakeven level. Our primary short-term objectives are to grow revenue while maximizing operating efficiencies, which can be achieved through controlling our working capital cash outlays and maintaining our strong expense controls. I’d now like to turn the call back over to Carl to discuss our 2017 guidance and plans.
Carl O’Connell: Thank you, John. The X [ph] of 2017 and beyond will be concentrated primarily on operational excellence while driving and maintaining above market growth. As the new CEO, my management team and I have already identified key areas of opportunity where we can realize significant cost synergies, efficiencies and overall areas of performance improvement contributes to overall profitability. There are still numerous cost saving opportunities that will remain untapped as a result of the integration of Bacterin and X-Spine. A specific examples is the implementation of successful inventory management supply chain controls improve forecasting processes including kit utilization and optimization and reconfiguration driving increased cash flow over this period and well into 2017. Within inventory management, we’re executing changes which will lead to improvements in the accuracy of our product demand forecast, enabling refine timing of inventory to accurately meet customer demand. This would allow Xtant’s provide customers the right product at the right place, at the right time. You may have noticed in our release yesterday that we have slightly reduced revenue guidance for 2017, while maintaining above market growth. This adjustment is a direct result of our current commitment to our new operational excellence programs driving new efficiencies and more profits. Both Xtant’s new CEO, I believe we’ll be a unique and successful player providing with genitive solutions as a true biologics and hard work fixation company. In the short-term, we will focus on operational excellence, stabilizing cash flow and continue to build year-on-year profitability, moving from uncertainty to predictability, establishing sound business fundamentals, capitalizing on a large distribution footprint, portfolio selling and national contract access. And then looking forward creating structure for growth and rounding out our portfolio products. So in closing, I want to thank our employees, sales partners, vendors and financial partners for working so hard to combine these two great companies. As always, we remain committed to the Donate Life Community and our recovery partners. Thank you for joining us today.
